
Opinion|Videos|February 25, 2025
Low-Sodium Oxybate in the Treatment of Narcolepsy and Idiopathic Hypersomnia
Author(s)R. Robert Auger, MD
An expert discusses the significance of low-sodium oxybate for patients with narcolepsy patients with and cardiovascular disease and compares the diagnostic criteria and clinical presentations of narcolepsy and idiopathic hypersomnia.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What is the significance of low-sodium oxybate formulations for patients with narcolepsy who have comorbid cardiovascular disease (CVD)?
- Low-sodium oxybate is also currently the only FDA-approved treatment for idiopathic hypersomnia (IH). How do the diagnostic criteria and clinical presentations of narcolepsy differ from those of IH?
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
1,700 sites closed, 77,000 fewer children received PEPFAR-supported treatment after PEPFAR disruption | IAS 2026
2
Payers lean on step therapy, formulary exclusions as IRA reshapes Part D benefit design
3
Redemplo cuts triglycerides, pancreatitis risk in severe hypertriglyceridemia
4
Step therapy requirements drive up time, costs in DME patients | ASRS 2026
5
























